Refinex ® botulinum toxin type A. Refinex Botox alternatives.
Refinex Botulinum toxin
Refinex is one of the top choice for those using Botox alternatives. Formulated with a snake venom ingredient, REFinex is an effective anti-wrinkle product that works due to a synthetic effect resulting from the venom of the Temple Viper. Refinex is made by the process of breeding and housing the unique snakes to capture the venoms’ peptides for use in cosmetics. Other ingredients in the Botox Alternative product include hexapeptide which is used to reduce muscle contraction. Sea-Weed Biopeptides are used in the formula primarily to enhance skin nutrition.
Refinex Botulinum Toxin type A –for therapy Refinex®botulinum toxin type A is a sterile and lyophilized highly purified protein produced from the cruded toxin of the culture of the hall strain of clostridium botulinum . it is produced in GMP (Good manufacturing practice) pharmaceutical factory. A simple treatment of Refinex ®botulinum toxin typeA can dramatically remove facial wrinkles and line. It’s also indicated for the treatment of belpharospasm, hemifacial spasm in adults and some types of strabismus, and hyper hidrosis etc. MORE EFFECTIVE Injections are extremely small doses of Refinex ® botulinum toxin type A can significantly relax specific facial muscles thus stopping them from contracting and cannot from wrinkles and lines.
Medical Research Institute, Japan
Richard Clark, a plastic surgeon from Sacramento (CA), was the first to document a cosmetic use for botulinum toxin. He treated forehead asymmetry caused by left sided forehead nerve paralysis that occurred during a cosmetic facelift. Since the injured nerve could possibly regenerate by 24 months, a two-year waiting period was necessary before definitive surgical treatment could be done. Clark realized that botulinum toxin, which had been previously used only for cross eyed babies and facial tics, could also be injected to smooth the wrinkles of the right forehead to match her paralyzed left. He received FDA approval for this cosmetic application of the toxin and successfully treated the person and published the case study in 1989.
Marrying ophthalmology to dermatology, Jean and Alistair Carruthers observed that blepharospasm patients who received injections around the eyes and upper face also enjoyed diminished facial glabellar lines (“frown lines” between the eyebrows), thereby initiating the highly-popular cosmetic use of the toxin. Brin, and a group at Columbia University under Monte Keen made similar reports. In 2002, following clinical trials, the FDA approved Botox Cosmetic, botulinum A toxin to temporarily improve the appearance of moderate-to-severe glabellar lines. The FDA approved a fully in vitro assay for use in the stability and potency testing of Botox in response to increasing public concern that LD50 testing was required for each batch sold in the market.
The cosmetic effect of BTX-A on wrinkles was originally documented by a plastic surgeon from Sacramento, California, Richard Clark, and published in the journal Plastic and Reconstructive Surgery in 1989. Canadian husband and wife ophthalmologist and dermatologist physicians, JD and JA Carruthers, were the first to publish a study on BTX-A for the treatment of glabellar frown lines in 1992. Similar effects had reportedly been observed by a number of independent groups (Brin, and the Columbia University group under Monte Keen. After formal trials, on April 12, 2002, the FDA announced regulatory approval of botulinum toxin type A (Botox Cosmetic) to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines). Subsequently, cosmetic use of botulinum toxin type A has become widespread. The results of Botox Cosmetic can last up to four months and may vary with each patient. The US Food and Drug Administration approved an alternative product-safety testing method in response to increasing public concern that LD50 testing was required for each batch sold in the market."